JAMA Oncology Response to Reviewers: How to Answer the Statistical Editor (2026)

State the exact page and line number for each manuscript revision, and reference the specific figure, table, checklist line, or supplementary file you changed. This is the single most-cited rebuttal failure at JAMA Oncology and across JAMA Network. A reviewer who has to hunt for your change reads it as evasion.

A statistical editor who can click straight to page 9, lines 4 to 19, and see the corrected model finishes faster and re-reviews more favorably. Never write "we have addressed this in the manuscript" without a location. Use the line numbers from the revised file, not the original, and note when a change is in a Supplement table or an eFigure rather than the main text.

The reviewers and the statistical editor see your tone across every comment, and a revision goes back through all three. A defensive reply to the statistical editor is the fastest way to lose a revision you could have won. Calibrate.

The pattern that works: concede where the reviewer is right, do the re-analysis, point to the exact change, and push back only on a request that is genuinely out of scope, with a reason and an alternative.

JAMA Oncology runs a separate statistical review alongside editorial and clinical peer review. JAMA Network embeds statistical editors in the process, so your analytical approach is examined by someone whose entire job is methodological scrutiny, and statistical concerns are reported directly to the editors and to you in the decision letter. The practical consequence for the rebuttal: the statistical editor's comments carry the most leverage over the decision, and they cannot be answered with reassurance.

When the statistician questions your model, your missing-data handling, or your power, the only answer that moves the decision is the corrected analysis with the new numbers.

The journal also holds a clinical-practice-impact and careful-interpretation bar that is unusual in its strictness. JAMA Oncology wants studies a practicing oncologist can act on, and it is openly skeptical of academic exercises without clinical relevance. At the same time, it rejects overinterpretation: if the primary endpoint did not meet significance, spinning a secondary analysis as practice-changing does not work.

The reviewers want absolute risk differences, confidence intervals, and number needed to treat, not p-value-focused reporting. So your rebuttal has to do two opposite things at once: show the clinical consequence is real, and refuse to claim more than the data prove.

Reporting discipline is enforced, not suggested. JAMA Network requires trial registration as a condition of consideration, expects a completed CONSORT flow diagram and checklist for trials, STROBE for observational studies, and PRISMA for systematic reviews, and requires a data sharing statement for research articles.

The April 2025 CONSORT 2025 update added an open-science section covering registration, protocol and analysis-plan access, data sharing, and disclosures, so a 2026 revision that completes a 2010-era checklist is already behind. On revision, every checklist item needs an accurate page number that matches the revised manuscript.

How this compares to the rest of the field matters for calibration. A response to reviewers at the main JAMA flagship faces an even broader-significance filter, while at NEJM the practice-changing bar is heavier still and at The Lancet Oncology the global-oncology framing carries weight. JAMA Oncology sits in a specific spot: top clinical-oncology significance, the strictest statistical review of the network's specialty titles, and a refusal to let interpretation outrun the analysis.

Because the statistical editor is a fixed part of the process, the bar for JAMA Oncology is closer to satisfying a biostatistician than satisfying a sympathetic clinical reader, which is not true at journals where statistics are reviewed only by the clinical referees.

In our pre-submission review work with JAMA Oncology manuscripts, the rebuttals that stall in a second revision round share a small set of recurring weaknesses. These are the same ones reviewers and the statistical editor flag at re-review. In our analysis of JAMA Oncology rebuttals, each weakness below maps to a specific, named failure pattern in the editorial culture, and each is testable against your own draft response before you upload it.

Answering a statistical comment with prose instead of re-analysis. The most common and most expensive pattern in our JAMA Oncology pre-submission reviews is a rebuttal that answers the statistical editor's request for a corrected model with a sentence added to the Methods. A statistical comment at JAMA Oncology means re-run the statistical analysis, not reword it.

When the statistician questions whether the result survives a competing-risk model or proper missing-data handling, adding a hedge to the Discussion does not move the decision; running the corrected model and reporting the new effect size and confidence interval does. Across our JAMA Oncology rebuttal reviews, this mismatch between what the statistical editor requested and what the author delivered is the single strongest predictor of a third round.

Overstating clinical implications the data do not support. Because JAMA Oncology screens hard for careful interpretation, a rebuttal that defends a practice-changing claim the primary endpoint does not support reads as not understanding the bar. In our JAMA Oncology pre-submission reviews we routinely find a conclusion that leans on a secondary endpoint or a subgroup, and a rebuttal that argues for the strong language rather than tempering it.

The revision that wins rewrites the Conclusions and the Key Points to state only what the data prove and moves the broader implication to a clearly framed limitation.

Incomplete or mismatched reporting-checklist fixes. A rebuttal that says "we have completed the CONSORT checklist" while the figure flow diagram still does not match the enrolled N, or where the checklist line numbers point to the old draft, forces a re-review comment.

In our pre-submission review work with JAMA Oncology manuscripts, responses that leave a reporting checklist half-fixed, or that omit the trial registration ID or the data availability statement, consistently draw a comment asking for the missing item, which adds a round. Every checklist line needs an accurate page and line number in the revised file.

Treating the statistical editor as a clinical reviewer. Because the statistical editor reads only for the numbers, a rebuttal that buries the re-analysis inside a long clinical reply, or that answers a methodological comment with clinical reassurance, makes the statistician hunt for the fix. In our JAMA Oncology pre-submission reviews, the rebuttals we flag hardest are the ones that never give the statistical editor a clean, numbered reply with the corrected estimate, the sample size justification, and the page and line of the revised methodology.

Re-run the analysis, temper the claim, complete every checklist, and answer the statistician in numbers. That four-part discipline is what separates a JAMA Oncology rebuttal that clears one revision round from one that stalls into a second or third. Check your JAMA Oncology point-by-point response for these patterns before you submit.

Source: Manusights pre-submission reviews of JAMA Oncology-targeted resubmissions, 2025 cohort.

Authors consistently underestimate the re-analysis effort and overestimate the writing effort. This breakdown is about workload, not the journal's decision clock; for the end-to-end decision schedule, see the JAMA Oncology review time guide.

Source: Manusights pre-submission reviews of JAMA Oncology resubmissions, 2025 cohort, last updated June 7, 2026.

A major-revision invitation at JAMA Oncology is not a soft acceptance. The revised manuscript and your point-by-point response go back through editorial, statistical, and clinical review, and the paper can still end in rejection after re-review if the corrected analysis weakens the headline result or if the clinical-practice claim still outruns the evidence. With a desk-rejection rate above 85% and an acceptance rate near 8%, the journal does not rubber-stamp revisions.

Most rejections at this stage trace to one cause: the author answered the statistical editor with prose instead of re-analysis. The second most common is a clinical claim the revised data still do not support.

Think twice before you resubmit if any of these are true. The response answers a statistical comment with reassurance rather than a re-run model. A reviewer flagged an overstated clinical implication and you argued for the strong language instead of tempering it. The CONSORT or STROBE checklist is still incomplete or its line numbers point to the old draft. The rebuttal uses generic "we have addressed this" language with no page or line numbers. Fixing these before resubmission is what keeps a second round from becoming a rejection.